EBI3 and diffuse large B-cell lymphoma: When classified by immunohistochemistry in GCB and non-GCB subtypes, representing the equivalents of the GCB and ABC cell types defined by molecular profiling, 71% of the GCB cases were positive for EBI3, while this percentage reached 85% among non-GCB cases (Figure 2C), indicating a slight over-representation of EBI3-negative cases among GCB DLBCL, in line with the molecular data from Dave et al. study.